Relationship between NR1I2 polymorphisms and inflammatory bowel disease risk: A systematic review and meta-analysis

Abstract

Background and objective: Inconsistent results regarding an association between polymorphisms within the Homo sapiens nuclear receptor subfamily 1 group I member 2 (NR1I2) gene and susceptibility to inflammatory bowel disease (IBD) have been reported. A systematic review and meta-analysis was thus undertaken to determine whether NR1I2 gene polymorphisms are associated with an increased risk of IBD.

Methods: Article retrieval was performed using on-line databases, such as PubMed, Embase, CENTRAL, and WOS. After extracting eligible data, Mantel-Haenszel statistics were applied to calculate the odds radio (OR), 95% confidence interval (95% CI) and P value under a random or fixed-effects model.

Results: A total of seven articles with 4410 IBD subjects and 4028 controls were included. Compared with the control group, no significant increase in IBD susceptibility was observed for the -25385C/T (OR=0.92, 95% CI=0.78∼1.07, P=0.259), -24381A/C (OR=0.96, 95% CI=0.87∼1.06, P=0.378), +8055C/T (OR=1.06, 95% CI=0.97∼1.15, P=0.186), or +7635A/G (OR=0.96, 95% CI=0.87∼1.05, P=0.348) polymorphisms within the NR1I2 gene under the allele model.

Conclusions: Our meta-analysis failed to demonstrate an association between -25385C/T, -24381A/C, +8055C/T, or +7635A/G polymorphisms within the NR1I2 gene and overall IBD risk. A larger sample size is needed to validate our conclusion.